CVS Health Co. (NYSE:CVS) Shares Sold by Northwest & Ethical Investments L.P.

Northwest & Ethical Investments L.P. reduced its position in CVS Health Co. (NYSE:CVS) by 17.4% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 13,268 shares of the pharmacy operator’s stock after selling 2,786 shares during the period. Northwest & Ethical Investments L.P.’s holdings in CVS Health were worth $834,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of CVS. Vinva Investment Management Ltd boosted its position in shares of CVS Health by 10.2% in the 3rd quarter. Vinva Investment Management Ltd now owns 56,446 shares of the pharmacy operator’s stock worth $3,465,000 after buying an additional 5,242 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in CVS Health by 1.6% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,049,945 shares of the pharmacy operator’s stock worth $443,301,000 after acquiring an additional 107,977 shares during the last quarter. Public Sector Pension Investment Board lifted its holdings in shares of CVS Health by 2.3% in the third quarter. Public Sector Pension Investment Board now owns 327,080 shares of the pharmacy operator’s stock valued at $20,567,000 after purchasing an additional 7,200 shares in the last quarter. Fiduciary Trust Co grew its position in shares of CVS Health by 0.3% in the third quarter. Fiduciary Trust Co now owns 108,151 shares of the pharmacy operator’s stock valued at $6,801,000 after purchasing an additional 375 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of CVS Health by 3.7% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 261,194 shares of the pharmacy operator’s stock worth $16,424,000 after purchasing an additional 9,418 shares in the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Stock Performance

NYSE CVS opened at $59.82 on Friday. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.80 and a quick ratio of 0.59. CVS Health Co. has a 1-year low of $52.71 and a 1-year high of $83.25. The firm has a market capitalization of $75.28 billion, a P/E ratio of 15.18, a P/E/G ratio of 1.02 and a beta of 0.55. The business’s 50-day simple moving average is $59.36 and its 200-day simple moving average is $58.74.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.01. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The firm had revenue of $95.43 billion for the quarter, compared to analysts’ expectations of $92.72 billion. During the same period in the previous year, the company posted $2.21 earnings per share. CVS Health’s revenue was up 6.3% compared to the same quarter last year. Equities analysts predict that CVS Health Co. will post 5.37 EPS for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Monday, October 21st were issued a $0.665 dividend. The ex-dividend date of this dividend was Monday, October 21st. This represents a $2.66 annualized dividend and a yield of 4.45%. CVS Health’s dividend payout ratio is currently 67.51%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on CVS. Deutsche Bank Aktiengesellschaft reduced their target price on CVS Health from $64.00 to $63.00 and set a “hold” rating on the stock in a research note on Friday, August 9th. TD Cowen increased their price objective on CVS Health from $73.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, November 25th. Evercore ISI lifted their price objective on CVS Health from $62.00 to $75.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Mizuho reduced their target price on shares of CVS Health from $73.00 to $66.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Finally, Wells Fargo & Company raised shares of CVS Health from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $60.00 to $66.00 in a research report on Monday, November 18th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $70.33.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.